- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Giant cell tumour of bone; Bone metastases
- Meeting Date: March 2025
- Public Summary Document (PSD) March 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2025 PBAC Meeting - (Word)
Denosumab – March 2025
Denosumab; Injection 120 mg in 1 mL single use pre-filled syringe; Xgeva®
Last updated
12 March 2025